AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00556478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is a metered dose aerosol spray that is identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing.~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period.
Trial: NCT00257881
Drug: CMD-193
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02397096
Drug: Baseline regimen of a non-nucleoside reverse transcriptase inhibitor
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular
Trial: NCT02397096
Drug: Baseline regimen of two nucleoside reverse transcriptase inhibitors
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular
Trial: NCT03542279
Drug: intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG is given 0.4 g/kg/d for each course for 5 days. IVMP is 1,000 mg or 500 mg methylprednisolone for 3 or 5 days, and the dosage of glucocorticoid will gradually decrease.
Trial: NCT00112034
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00112034
Drug: IV methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02313675
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003459
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with a brain stem glioma will receive Antineoplaston therapy (Atengenal + Astugenal)
Trial: NCT01181154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: equivalent volume total
Trial: NCT02052440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill by mouth three times daily
Trial: NCT00306475
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo identical in appearance to active comparator
Trial: NCT01333605
Drug: IGEV
RxNorm normalized name: Intravenous Immunoglobulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles.
Trial: NCT00090519
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD oral for up to 36 months
Trial: NCT00347204
Drug: ketorolac (Acular LS)
RxNorm normalized name: ketorolac Ophthalmic Solution [Acular]
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00347204
Drug: Nepafenac (Nevanac)
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01183767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02378649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator concomitant with best practice usual care
Trial: NCT04094519
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT03301870
Drug: ATx201 Gel 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% active gel
Trial: NCT03301870
Drug: ATx201 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo gel
Trial: NCT00715351
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
Trial: NCT03115099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03322995
Drug: First-line Chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first-line therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or best available standard of care.
Trial: NCT03322995
Drug: Second-line Chemotherapy
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second line therapies will be multi-agent and contain gemcitabine. Molecular profiling data from the initial endoscopic ultrasound (EUS)/ fine needle aspirate (FNA) biopsy may be used at the discretion of the treating physician.
Trial: NCT02261805
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00357994
Drug: Levodopa carbidopa intestinal gel (LCIG)
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)
Trial: NCT00357994
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00357994
Drug: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00357994
Drug: Placebo (PBO) oral capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03926702
Drug: Radiopharmaceuticals
RxNorm normalized name: RADIOPHARMACEUTICALS,DIAGNOSTIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive radiopharmaceutical for positron-emission tomography (PET) scan.
Trial: NCT00345046
Drug: EconoPred Plus
RxNorm normalized name: Econopred Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone Acetate four times daily decreasing to once daily over four weeks.
Trial: NCT00345046
Drug: Prednisolone Acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosed four times daily decreasing to once daily over four weeks.
Trial: NCT03244800
Drug: MEDI0382
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI0382 will be administered subcutaneously once daily for 49 days.
Trial: NCT03244800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously once daily for 49 days.
Trial: NCT02897206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An imipenem-matching placebo
Trial: NCT01692769
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
Trial: NCT01692769
Drug: Ringer's Lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
Trial: NCT04121715
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refer to the Guidelines for Rational Use of Coronary Heart Diseases.rational selection of antiplatelet drugs, statins, etc. according to the patient's condition
Trial: NCT01972906
Drug: Ibuprofen Sustained Release Capsules
RxNorm normalized name: ibuprofen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apply Ibuprofen (H20013062), 0.3g， Bid, lasting 3 days before menstrual cycle
Trial: NCT03732807
Drug: PF-06651600 Induction Dose
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets taken once daily (QD)
Trial: NCT03732807
Drug: PF-06651600 Maintenance Dose #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets taken QD
Trial: NCT03732807
Drug: PF-06651600 Maintenance Dose #2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets taken QD
Trial: NCT03732807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets taken QD
Trial: NCT01779700
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet each day of 8 week cycle
Trial: NCT02966652
Drug: DITEST
RxNorm normalized name: Meditest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid formulation of native oral testosterone.
Trial: NCT03451422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
Trial: NCT01115140
Drug: Metformin plus folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metformin 850 mg cp, 2 cps daily plus folic acid 0.4 mg daily
Trial: NCT01115140
Drug: placebo plus folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 cp daily plus folic acid 0.4 mg daily
Trial: NCT03306498
Drug: Aminoleban (8% amino acids infusion)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 1000ml of AMINOLEBAN contains: Aminoacetic acid - 9.0 g L-alanine -- 7.5 g L-arginine Hydrochloride (HCl) -- 7.3 g (L-arginine equivalent) -- (6.0 g) L-cysteine HCl monohydrate -- 0.4 g (L-cysteine equivalent) -- (0.3 g) L-histidine HCl monohydrate -- 3.2 g (L-histidine equivalent)-- (2.4 g) L-isoleucine -- 9.0 g L-leucine -- 11.0 g L-Lysine HCl -- 7.6 g (L-lysine equivalent) -- (6.1 g) L-methionine -- 1.0 g L-phenylalanine -- 1.0 g L-proline -- 8.0 g L-serine -- 5.0 g L-threonine -- 4.5 g L-tryptophan -- 0.7 g L-valine -- 8.4 g Water for injection q.s -- 1000 m
Trial: NCT03274076
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo 5 mg twice a day for 24 weeks
Trial: NCT02553889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT03781375
Drug: Placebo to Etanerceot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection twice a week
Trial: NCT03781375
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally or subcutaneously once a week at the same dose as prior to study entry
Trial: NCT02909959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets are uncoated and matched in appearance to the investigational medicinal product, containing inert components. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
Trial: NCT04639869
Drug: Cabral 400 mg Film Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.
Trial: NCT02973594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03739866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously in the abdomen
Trial: NCT00853580
Drug: Lovastatin ™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin starting at 20mg for 2 weeks, increasing to 40mg for 14 weeks. Total duration of trial is 16 weeks.
Trial: NCT05427305
Drug: TAB008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
Trial: NCT01359150
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).
Trial: NCT01034306
Drug: CF101
RxNorm normalized name: CF101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally q12h
Trial: NCT01034306
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally q12 hours
Trial: NCT00491894
Drug: Oral Glycopyrrolate Liquid
RxNorm normalized name: glycopyrrolate Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver
Trial: NCT05340452
Drug: Klaribact 125mg/5ml Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one single 20 mL dose (500mg) of the test drug will be administered to the volunteers
Trial: NCT05340452
Drug: Klaricid 125mg/5ml Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one single 20 mL dose (500mg) of the Reference drug will be administered to the volunteers
Trial: NCT01116206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, orally once dailyfor 12 weeks
Trial: NCT04176952
Drug: FOLFOX-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).~* Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.~* Folinic acid: 350mg flat dose, IV over 2 hours, day 1.~* Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)
Trial: NCT04176952
Drug: AG
RxNorm normalized name: AGP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).~* Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel).
Trial: NCT03717467
Drug: isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
Trial: NCT00587275
Drug: AST-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, sachet, 2 grams daily for 4 weeks
Trial: NCT01759862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
Trial: NCT00405184
Drug: IntragamP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IntragamP - dosage based on previous dose of IntragamP prior to study entry. One cycle (Cycle 0)only administered, with dosage calculation based on body weight on Day 1 of the study and must be between 0.2-0.8 g/kg body weight. IntragamP to be administered intravenously.
Trial: NCT00405184
Drug: Ig NextGen 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ig NextGen 10% - dosage based on previous dose of IntragamP in Cycle 0. Dosage calculation to use body weight on Day 1 of Cycle 1 of the study and must be between 0.2-0.8 g/kg body weight. 7 cycles administered, and patients to be dosed at 3 to 4 week intervals (in accordance with previous dosage schedule with IntragamP). Ig NextGen 10% to be administered intravenously.
Trial: NCT04864782
Drug: QL1604
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion
Trial: NCT01896843
Drug: STX107
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04777383
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iontophoretic administration of 5 different concentrations of acetylcholine
Trial: NCT04777383
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iontophoretic administration of 5 different concentrations of norepinephrine
Trial: NCT01077700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive substance
Trial: NCT03683576
Drug: GB001
RxNorm normalized name: Glebretinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated oral tablet
Trial: NCT03683576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated oral tablet
Trial: NCT01593020
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
Trial: NCT01593020
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.
Trial: NCT02170337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains no active drug
Trial: NCT00145470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo fast dissolving SL tablets, BID
Trial: NCT03853538
Drug: BAY207543 (Bepanthol, Bepantol® Derma Spray)
RxNorm normalized name: Derma Gran Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product is applied to one hemiface.
Trial: NCT04124887
Drug: Xylitol-coated calcium and phosphate
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varnish with Xylitol-coated calcium and phosphate was applied to the targeted teeth at baseline, one and three months.
Trial: NCT01044888
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 U/kg heparin was administered intravenously at the beginning of graft anastomosis and accepted a perioperative ACT value of around 300 s. Ten minutes after the loading dose, the ACT was measured. An ACT of 300 s or greater was considered as adequate. Then follow up ACT measurement was determined after 30 min from the previous ACT measurement. If ACT fell below the target value of 300 s, an additional dose of heparin was administered. If ACT was between 250 and 299 s, additional 2000 U of heparin was administered and if ACT was between 200 and 249 s then additional 3000 U of heparin was injected. Ten minutes after additional heparin injection, ACT was remeasured.
Trial: NCT04379869
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator for double-blind MAD
Trial: NCT02063659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching telotristat etiprate tablets
Trial: NCT04044781
Drug: BPN14770, T2310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.
Trial: NCT01000805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo QD, po for 8 weeks.
Trial: NCT01800487
Drug: silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 mg three times a day for 4 weeks
Trial: NCT01800487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (silymarin) 1 tab three times a day for 4 weeks
Trial: NCT01412736
Drug: KHK4563
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
Trial: NCT01412736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
Trial: NCT00220805
Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.
Trial: NCT00220805
Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
Trial: NCT00028548
Drug: R(+)XK469
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00070486
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given PO
Trial: NCT00692913
Drug: FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
Trial: NCT01064999
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CRT:625mg/m2,bid,d1-5,q week RT:1000mg/m2,bid,d1-14,q 3 weeks
Trial: NCT00042965
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03158506
Drug: HMS5552
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-labelled HMS5552